Abstract: A number of selected genes/gene products; Application of selected genes/gene products at mRNA or protein levels either singly or in combination; Application of selected genes/gene products at mRNA levels by any of the methods such as: Northern blotting, or reverse transcription and conventional PCR, or reverse transcription and quantitative real-time PCR or gene expression micro-arrays; Application of selected genes/gene products at protein levels by either Western Blotting, or immunohistochemistry, or ELISA or functional assays or gel electrophoretic separation followed by spectroscopic identification (proteamics); Application of selected genes/gene products at peptide levels derived from proteins and spectroscopic methods of identification; Detection of a hyperproliferative condition, a precancerous condition, a predisposition to develop hyperproliferative condition or cancer by applying any one of the selected genes either singly or in combination in breast tissue, breast fluid, breast cells, blood or any

Abstract: A method of amplifying and quantifying a mRNA transcript of the &agr; or &bgr; isoform of the ER; a method of generating an expression profile of mRNA transcripts of the &agr; or &bgr; isoform of the ER, wherein the mRNA transcripts comprise wild-type or alternatively spliced exons, comprising reverse-transcribing the mRNA transcript, amplifying the resulting cDNA using a targeted primer and a partner primer, contacting the resulting amplicons with a probe, detecting the probe, and quantifying the detected probe; isolated oligonucleotides to be used as a targeted primer, partner primer, or probe; a method of determining a hyperproliferative condition or a predisposition to a hyperproliferative condition, such as breast cancer or a risk for breast cancer; a method of screening candidate therapeutic treatments for an ER-sensitive condition; and a method of prognosticating response of a mammal to a therapeutic treatment of breast cancer; and other methods.